ANEW MEDICAL, INC. Appoints New CFO
ANEW MEDICAL (NASDAQ: WENA), a U.S. biotechnology company focused on cell and gene-based treatments for aging and age-related diseases, has appointed Jeffrey LeBlanc as its new Chief Financial Officer (CFO). LeBlanc replaces interim CFO Edward Cong Wang, who was previously the CFO of Redwoods Acquisition Corp, with which ANEW merged.
Dr. Joseph Sinkule, ANEW's Founder, Chairman, and CEO, praised LeBlanc's appointment, highlighting his over 20 years of experience in managing financial operations, launching new ventures, and achieving successful exits. LeBlanc's background includes investment roles at Greenlight Capital and GE Capital, as well as a stint at McKinsey and Co. He holds a BS in Chemical Engineering from MIT and an MBA from Harvard Business School.
ANEW MEDICAL (NASDAQ: WENA), una società biotecnologica statunitense focalizzata su trattamenti basati su cellule e geni per l'invecchiamento e le malattie correlate all'età, ha nominato Jeffrey LeBlanc nuovo Chief Financial Officer (CFO). LeBlanc sostituisce l'attuale CFO ad interim Edward Cong Wang, che in precedenza era CFO di Redwoods Acquisition Corp, con cui ANEW si è fusa.
Il Dott. Joseph Sinkule, fondatore, presidente e CEO di ANEW, ha elogiato la nomina di LeBlanc, evidenziando la sua oltre ventennale esperienza nella gestione delle operazioni finanziarie, nel lancio di nuove iniziative e nel conseguimento di exit di successo. Il percorso professionale di LeBlanc include ruoli di investimento in Greenlight Capital e GE Capital, oltre a un periodo trascorso presso McKinsey and Co. Ha conseguito una laurea in Ingegneria Chimica al MIT e un MBA presso la Harvard Business School.
ANEW MEDICAL (NASDAQ: WENA), una compañía de biotecnología estadounidense centrada en tratamientos basados en células y genes para el envejecimiento y enfermedades relacionadas con la edad, ha nombrado a Jeffrey LeBlanc como su nuevo Chief Financial Officer (CFO). LeBlanc reemplaza al CFO interino Edward Cong Wang, quien fue CFO de Redwoods Acquisition Corp, con la que ANEW se fusionó.
Dr. Joseph Sinkule, fundador, presidente y CEO de ANEW, elogió el nombramiento de LeBlanc, subrayando su más de 20 años de experiencia en la gestión de operaciones financieras, lanzando nuevas iniciativas y logrando salidas exitosas. La trayectoria de LeBlanc incluye roles de inversión en Greenlight Capital y GE Capital, así como una etapa en McKinsey and Co. Tiene una licencia en Ingeniería Química del MIT y un MBA de la Harvard Business School.
ANEW MEDICAL (NASDAQ: WENA), 미국의 생명공학 회사로 세포와 유전자 기반의 노화 및 노화 관련 질병 치료에 초점을 맞추고 있으며, Jeffrey LeBlanc를 새로운 최고 재무 책임자(CFO)로 임명했습니다. LeBlanc는 ANEW가 합병한 Redwoods Acquisition Corp의 CFO였던 임시 CFO Edward Cong Wang을 대신합니다.
ANEW의 창립자이자 의장, CEO인 Dr. Joseph Sinkule는 LeBlanc의 임명을 칭찬하며 그의 재무 운영 관리, 새로운 기업 출범, 성공적인 퇴출 달성에 관한 20년 이상의 경험을 강조했습니다. LeBlanc의 경력에는 Greenlight Capital 및 GE Capital에서의 투자 역할과 McKinsey and Co에서의 경력이 포함됩니다. 그는 MIT에서 화학공학 학사 학위를 받고 하버드 경영대학원에서 MBA를 취득했습니다.
ANEW MEDICAL (NASDAQ: WENA), une entreprise de biotechnologie américaine spécialisée dans les traitements basés sur les cellules et les gènes pour le vieillissement et les maladies liées à l'âge, a nommé Jeffrey LeBlanc nouveau directeur financier (CFO). LeBlanc remplace le CFO par intérim Edward Cong Wang, qui était auparavant CFO de la Redwoods Acquisition Corp, avec laquelle ANEW a fusionné.
Le Dr Joseph Sinkule, fondateur, président et PDG d'ANEW, a salué la nomination de LeBlanc, soulignant sa plus de 20 ans d'expérience dans la gestion des opérations financières, le lancement de nouvelles activités et la réalisation d'exits réussies. Le parcours de LeBlanc inclut des rôles d'investissement chez Greenlight Capital et GE Capital, ainsi qu'une expérience chez McKinsey and Co. Il a obtenu un diplôme en Génie chimique au MIT et un MBA à la Harvard Business School.
ANEW MEDICAL (NASDAQ: WENA), ein US-amerikanisches Biotechnologieunternehmen, das sich auf zell- und genbasierte Behandlungen für das Altern und altersbedingte Krankheiten konzentriert, hat Jeffrey LeBlanc zum neuen Chief Financial Officer (CFO) ernannt. LeBlanc tritt die Nachfolge des interimistischen CFO Edward Cong Wang an, der zuvor CFO der Redwoods Acquisition Corp war, mit der ANEW fusionierte.
Dr. Joseph Sinkule, der Gründer, Vorsitzende und CEO von ANEW, lobte die Ernennung von LeBlanc und hob seine über 20-jährige Erfahrung in der Leitung finanzieller Abläufe, bei der Gründung neuer Unternehmen und bei der erfolgreichen Umsetzung von Exits hervor. LeBlancs beruflicher Werdegang umfasst Investitionsrollen bei Greenlight Capital und GE Capital sowie eine Station bei McKinsey and Co. Er hat einen Bachelor-Abschluss in Chemieingenieurwesen vom MIT und einen MBA von der Harvard Business School.
- Appointment of a highly experienced CFO with over 20 years in financial operations
- New CFO has a strong background in investment roles and successful exits
- Jeffrey LeBlanc brings expertise from prestigious firms like Greenlight Capital and GE Capital
- None.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company’s Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged.
“Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team,” commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. “Jeff has over 20 years of experience in managing financial operations, launching new ventures and achieving successful exits. Earlier in his career, Jeff served in investment roles at Greenlight Capital and GE Capital, after having started his career at McKinsey and Co following his graduation from MIT with a BS in Chemical Engineering and subsequently an MBA from Harvard Business School.”
About ANEW MEDICAL, INC.
ANEW MEDICAL, INC. (NASDAQ: WENA), a biopharmaceutical company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis and rare neurodegenerative diseases. ANEW’s current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called NanojectTM. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@anewmeds.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
Who is the new CFO of ANEW MEDICAL (WENA)?
What is Jeffrey LeBlanc's background before joining ANEW MEDICAL (WENA)?
Who did Jeffrey LeBlanc replace as CFO at ANEW MEDICAL (WENA)?
What is ANEW MEDICAL's (WENA) focus as a biotechnology company?
